PARIS, March 6- Bouygues on Thursday made an offer for larger telecom rival SFR, which promises a bigger potential payday for seller Vivendi than a competing offer from Numericable but has more regulatory risks.» Read More
P&G has been one of the great growth companies of all times but quite frankly it has stumbled over the past couple of years under the current CEO's leadership, said William Ackman, Pershing Square Capital Management founder & CEO, discussing the problems at Procter & Gamble.
In this excerpt from a "Squawk Box" interview on October 2, 2012, Pershing Square's Bill Ackman said he had bought some stock and expressed his concerns about the company to its Board.
In court documents that lawyers for Bain Capital sought to keep secret, the company and other leading private equity firms are depicted as unofficial partners in a bid-rigging conspiracy aimed at holding down the prices of businesses they were seeking to buy, The New York Times reports.
Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to play the health care space.
Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to trade financials after the banking crisis.
"Ultimately, I don't think lower rates make that much difference anymore," says Dinakar Singh, TPG-Axon Capital CEO, sharing his thoughts on additional Fed easing.
CNBC's Kayla Tausche reports Hertz is upping its bid for Dollar Thrifty, and a look at how to play the takeover bid, with Fred Lowrance, Avondale Partners.
CNBC's David Faber reports shareholder activism is on the rise and Nelson Peltz is taking a seat on the board at Ingersoll-Rand.
Checking the charts on Research in Motion and the rumor that IBM is looking to buy one of RIM's main units, with Edward Snyder, Charter Equity Research, and Abigail Doolittle, Peak Theories Research.
CNBC's David Faber breaks down the profit-making divisions within the media giant; including its cable, film, television, satellite and publishing units.
Peter Misek, Jefferies senior tech analyst, explains why Samsung could be a potential candidate to purchase Research in Motion.
Richard Ill, Triumph Group chairman, explains how the aircraft supplier has managed to gain from Boeing's loss and profit from recent takeovers.
The co-founder of the trailblazing private-equity firm Kohlberg Kravis Roberts is actively involved in managing the firm famous for its leveraged buyout of RJR Nabisco 25 years ago.
CNBC's David Faber reports Glaxo will buy Human Genome for $14.24 per share, and TPG acquires generic drugmaker Par Pharma.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
CNBC's Jon Fortt reports the latest details from RIM's annual shareholders meeting and Colin Gillis, BGC Partners analyst, discusses whether there are investment opportunities in the stock despite its downward spiral.
Here are five companies that could be bought, according to analyst Ken Hackel of CT Capital, best known for his book, “Security Valuation and Risk Analysis.”
Mad Money's Jim Cramer answers e-mails from viewers on stock and investment questions.
Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.
CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.